Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.77 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL1B | P01584 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21304403 | 1.00 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1096812 | 0.93 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19611998 | 0.93 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19611996 | 0.93 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23168704 | 0.90 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19308802 | 0.90 | DDB1 (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20260405 | 0.89 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL14085396 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15502703 | 0.88 | DDB1 (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1963076 | 0.88 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2008-11-20 | — | — | US | claimed |
| EP-4683934-A1 | SYSTEM | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024194645-A1 | SYSTEM | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-09-26 | — | — | WO | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024006403-A2 | SELECTIVE HISTONE DEACETYLASE 8 (HDAC8) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-7820697-B2 | Compositions and method for reducing TNFα levels | CELGENE CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2008-11-20 | — | — | US | disclosed |
| WO-2008115516-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20060030592-A1 | I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2006-02-09 | — | — | US | disclosed |
| EP-1357120-A1 | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-6403613-B1 | ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) | CELGENE CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | MAN HON-WAH (US) | 2001-07-05 | — | — | US | disclosed |
| EP-1064277-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | Gelgene Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047512-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | COLGENE CORPORATION (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030592-A1 | I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | DDB1 668/4885CRBN 4100/4885IKZF3 97/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DDB1 433/4885CRBN 3/4885IKZF3 3470/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | DDB1 594/4885CRBN 5/4885IKZF3 719/4885 |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | DDB1 621/4885CRBN 4056/4885IKZF3 275/4885 |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | TNF, IL1A, IL1B | DDB1 733/4885CRBN 4134/4885IKZF3 275/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | DDB1 256/4885CRBN 1/4885IKZF3 208/4885 |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | TNF, IL1A, IL1B | DDB1 733/4885CRBN 4134/4885IKZF3 275/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | DDB1 809/4885CRBN 3/4885IKZF3 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.